Two distinct phenotypes of immunologically hot gastric cancer subtypes

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA A Cancer J. Clin., 71, 209, 10.3322/caac.21660 Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 390, 2461, 10.1016/S0140-6736(17)31827-5 Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial, JAMA Oncol, 4, 10.1001/jamaoncol.2018.0013 Shitara, 2018, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial, Lancet, 392, 123, 10.1016/S0140-6736(18)31257-1 Shitara, 2020, Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial, JAMA Oncol, 6, 1571, 10.1001/jamaoncol.2020.3370 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480 Cristescu, 2015, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes, Nat. Med., 21, 449, 10.1038/nm.3850 Han, 2021, Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures, Immun Inflamm Dis Lin, 2021, Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer, NPJ Genom Med, 6, 83, 10.1038/s41525-021-00249-x Sato, 2020, Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells, Clin Transl Immunology, 9, e1194, 10.1002/cti2.1194 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 550, 10.1186/s13059-014-0550-8 Kishton, 2017, Metabolic regulation of T cell longevity and function in tumor immunotherapy, Cell Metabol., 26, 94, 10.1016/j.cmet.2017.06.016 Eikawa, 2015, Immune-mediated antitumor effect by type 2 diabetes drug, metformin, Proc. Natl. Acad. Sci. U.S.A., 112, 1809, 10.1073/pnas.1417636112 Molina, 2018, An inhibitor of oxidative phosphorylation exploits cancer vulnerability, Nat. Med., 24, 1036, 10.1038/s41591-018-0052-4 Nishida, 2021, Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes, J Immunother Cancer, 9, 10.1136/jitc-2021-002954 Yang, 2004, Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis, Cell, 117, 927, 10.1016/j.cell.2004.06.006 Onder, 2008, Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways, Cancer Res., 68, 3645, 10.1158/0008-5472.CAN-07-2938 Zhao, 2021, Overview on the role of E-cadherin in gastric cancer: dysregulation and clinical implications, Front Mol Biosci, 8, 10.3389/fmolb.2021.689139 Padmanaban, 2019, E-cadherin is required for metastasis in multiple models of breast cancer, Nature, 573, 439, 10.1038/s41586-019-1526-3 Finotello, 2019, Next-generation computational tools for interrogating cancer immunity, Nat. Rev. Genet., 20, 724, 10.1038/s41576-019-0166-7